Drug Profile


Alternative Names: Captisol®-enabled pevonedistat; MLN-4924; TAK-924

Latest Information Update: 26 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Takeda Oncology
  • Class 2 ring heterocyclic compounds; Amines; Antineoplastics; Cyclopentanes; Indenes; Pyrimidines; Pyrroles; Small molecules; Sulfonic acids
  • Mechanism of Action NEDD 8 activating enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • No development reported Haematological malignancies
  • Discontinued Solid tumours

Most Recent Events

  • 07 Aug 2017 Vanderbilt-Ingram Cancer Center and National Cancer Institute plan a phase II trial for Myelodysplastic syndromes and Myeloproliferative disorders (Second-line therapy or greater, Combination therapy, Refractory metastatic disease, Late-stage disease) in USA (NCT03238248)
  • 26 Jul 2017 University of Michigan Cancer Center plans a phase II trial for Non-small cell lung cancer (Treatment-experienced, Late-stage disease) in USA (NCT03228186)
  • 05 Jul 2017 City of Hope Medical Center and National Cancer Institute initiates enrolment in a phase I trial for Acute myeloid leukaemia (Combination therapy) in USA (NCT03009240)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top